All In Biotech

NDA 220406 · Avyxa Holdings

Vykoura

Leucovorin Calcium · Intramuscular, Intravenous

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 3, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,213

522 Phase 3, 324 recruiting

FAERS reports

19,528

17,681 serious, 2,620 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2026.

VYKOURA is indicated for: 1.1 Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients. 1.2 Reducing the toxicity of: Methotrexate in adult and pediatric patients with impaired methotrexate elimination or Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients. 1.3 Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. 1.4 Treatment of patients with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use VYKOURA is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. VYKOURA is a folate analog indicated for: Rescue after high-dose methotrexate therapy in adult and pediatric patients. ( 1.1 ) Reducing the toxicity of methotrexate in adult and pediatric patients with impaired methotrexate elimination or folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients. ( 1.2 ) Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. ( 1.3 ) Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil. ( 1.4 ) Limitations of Use : VYKOURA is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. ( 1.3 )

Mechanism: High-Dose Methotrexate Therapy Leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF). The biologically active compound of the mixture is the (-)- l isomer, known as Citrovorum factor or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of "one-carbon" moieties. l -Leucovorin (l-5 formyltetrahydrofolate) is rapidly metabolized (via 5, 10-methenyltetrahydrofolate then 5, 10-methylenetetrahydrofolate) to l -5-methyltetrahydrofolate. L...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 3, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
3 products under this application
  • VYKOURA · LEUCOVORIN CALCIUM EQ 500MG BASE/50ML (EQ 10MG BASE/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription
  • VYKOURA · LEUCOVORIN CALCIUM EQ 50MG BASE/5ML (EQ 10MG BASE/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription
  • VYKOURA · LEUCOVORIN CALCIUM EQ 350MG BASE/35ML (EQ 10MG BASE/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leucovorin" as an intervention, any sponsor and status, largest first.

All 2,213 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,833
  • nausea1,441
  • vomiting1,165
  • neutropenia1,131
  • pyrexia1,037
  • off label use985
  • fatigue906
  • disease progression798
  • drug ineffective734
  • dyspnoea727
  • asthenia694
  • abdominal pain686

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004944
2005789
2006647
2007764
2008889
2009618
2010457
2011886
20121,250
2013251
2014223
2015192
2016218
2017284
2018412
2019498
2020474
2021886
20221,952
20231,711
20241,856
20251,958
20261,369

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,494 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.